Details for Patent: 7,741,374

Which drugs does patent 7,741,374 protect, and when does it expire?

Patent 7,741,374 protects FIBRICOR and is included in one NDA.

Summary for Patent: 7,741,374

Patent landscape, scope, and claims:

Title:	Methods of use of fenofibric acid
Abstract:	Fenofibric acid formulations comprising 105 mg of fenofibric acid are described as well as methods of use thereof. Dosage forms include, for example, immediate-release dosage forms.
Inventor(s):	Arnold; Kristin Anne (Morrisville, PA), Feng; Hengsheng (Cherry Hill, NJ)
Assignee:	Mutual Pharmaceutical Company, Inc. (Philadelphia, PA)
Application Number:	12/556,644
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 7,741,374

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Athena	FIBRICOR	fenofibric acid	TABLET;ORAL	022418-001	Aug 14, 2009		DISCN	Yes	No	7,741,374					ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA
Athena	FIBRICOR	fenofibric acid	TABLET;ORAL	022418-001	Aug 14, 2009		DISCN	Yes	No	7,741,374					ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS
Athena	FIBRICOR	fenofibric acid	TABLET;ORAL	022418-002	Aug 14, 2009		DISCN	Yes	No	7,741,374					ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA
Athena	FIBRICOR	fenofibric acid	TABLET;ORAL	022418-002	Aug 14, 2009		DISCN	Yes	No	7,741,374					ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS